Effect of trifunctional bispecific antibody (BiLu) on GVHD and GVT induction by BALB/c spleen cells in mice inoculated with a sublethal dose of melanoma cells
. | . | Cause of death, no. . | . | . | |
|---|---|---|---|---|---|
| Effector cells and BiLu pretreatment . | Median survival, d (range) . | Tumor . | GVHD . | No. disease-free survivors . | |
| No splenocytes | |||||
| No BiLu pretreatment | 33 (24-212) | 60 | NA | 7 | |
| BiLu pretreatment | > 212 (24-> 212) | 3 | NA | 7 | |
| Splenocytes, one dose | |||||
| No BiLu pretreatment | 66 (26-> 212) | 18 | 1 | 13 | |
| BiLu pretreatment | > 212 (43-> 212) | 1 | 0 | 19 | |
| Splenocytes, two doses | |||||
| No BiLu pretreatment | > 148 (23-> 280) | 6* | 7† | 14‡ | |
| BiLu pretreatment | > 212 | 0* | 0† | 10‡ | |
. | . | Cause of death, no. . | . | . | |
|---|---|---|---|---|---|
| Effector cells and BiLu pretreatment . | Median survival, d (range) . | Tumor . | GVHD . | No. disease-free survivors . | |
| No splenocytes | |||||
| No BiLu pretreatment | 33 (24-212) | 60 | NA | 7 | |
| BiLu pretreatment | > 212 (24-> 212) | 3 | NA | 7 | |
| Splenocytes, one dose | |||||
| No BiLu pretreatment | 66 (26-> 212) | 18 | 1 | 13 | |
| BiLu pretreatment | > 212 (43-> 212) | 1 | 0 | 19 | |
| Splenocytes, two doses | |||||
| No BiLu pretreatment | > 148 (23-> 280) | 6* | 7† | 14‡ | |
| BiLu pretreatment | > 212 | 0* | 0† | 10‡ | |
F1 mice were inoculated with B16-EpCAM melanoma cells (5 × 103) 24 hours after conditioning with 4 Gy TBI. One day later, naive BALB splenocytes (30 × 106 per dose) administered once or twice, as indicated at an interval of 5 days were given intraperitoneally with or without pretreatment with BiLu (10 μg per mouse). P values are shown for the comparison of tumor-and GVHD-related death as well as for disease-free survivors with or without BiLu treatment. Cell therapy with 2 doses versus 1 dose of BALB splenocytes, both without BiLu, significantly (P = .006) reduced the number of tumor-related deaths, significantly (P = .039) increased the number of GVHD-related deaths, but was not statistically different for the disease-free survivors (P = .186). Unless otherwise indicated, P < .001.
NA indicates not applicable.
P = .109
P = .031
P = .007